This is a Phase 2, randomized, placebo-controlled, multicenter, parallel-group, dose-ranging study in patients with PA to evaluate the efficacy and safety of up to 3 doses of CIN-107 as compared to placebo after 4 weeks of treatment.

Study Name: A Study of CIN-107 in Adults With Primary Aldosteronism (spark-PA)
Status: Not yet recruiting
Conditions: Primary aldosteronism, Hyperaldosteronism
Interventions: Drug: CIN-107 Dose 1, Drug: CIN-107 Dose 2, Drug: CIN-107 Dose 3, Drug: Placebo for CIN-107
Locations: CinCor Site 02, Ann Arbor, Michigan, United States, 48109, and CinCor Site 01, Rochester, Minnesota, United States, 55905
Study link:

To search for other studies by topic, location, or status, go to our Clinical Studies page.